Although new classifications for neuroendocrine tumors were established by the World Health Organization, the current procedures and terms used in pathology laboratories are not known. A Web-based questionnaire was distributed to 491 institutions affiliated with the Japanese Society for Cancer of the Colon and Rectum, and 150 participated. 
Introduction
Since the first proposal of Oberndorfer for the classification of carcinoid tumors 1 , this lesion has been characterized by neoplastic cells with otherwise endocrine properties and a phenotype that has been recognized and studied in not only gastrointestinal organs, but also the lung, endocrine organs, and others 2 . The wide distribution of this tumor has caused a lack of standard nomenclature and staging classification; it has been reported as a carcinoid tumor, endocrine tumor, endocrine carcinoma, or small cell carcinoma with various staging systems [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . The World Health Organization (WHO) Classification of the Digestive System 2010 adopted the term "neuroendocrine neoplasm" to bridge this classification gap. Using mitotic count and Ki-67 index, researchers have further classified neuroendocrine neoplasms into neuroendocrine tumor (NET) G1, NET G2, and neuroendocrine carcinoma (NEC) 14 . Next, Klimstra et al. proposed a minimum pathology data set for diagnosing gastrointestinal NET, and important pathology data that should appear in routine reports were selected using the Delphic consensus development method 15 . However, the degree of acceptance in Japan of this NET classification and reporting system in routine pathology diagnosis has not been investigated. A detailed understanding of the current practices in the diagnosis of NET may reveal underlying problems in routine practice, and therefore, the Japanese Society 
Material and Methods

Nationwide Web Survey
The nationwide Web survey was conducted from November 1, 2013 to December 16, 2013 within multiple pathology laboratories under institutions belonging to the JSCCR.
It was performed in accordance with ethical guidelines for clinical studies and considered the patients' human rights and privacy. The study protocol was approved by the institutional review board of JSCCR. In total, 491 pathology laboratories were invited by mailed invitation letter to participate in the online Web survey. The questionnaire in this survey included questions about reporting criteria, types of routine immunohistochemical and histochemical stains used, and procedures for the assessment of colorectal NET. The questionnaire was sent to the laboratories in Japanese and the table is only the translated version (Table 1) . Because the Japanese Classification of Colorectal Carcinoma (JCCC) 7 th edition adopted "carcinoid tumor" as their nomenclature 16 , as opposed to "neuroendocrine tumor" in the WHO 2010
Classification, one question we asked was which term was used in daily practice. The study was approved by the institutional review board of the JSCCR. 
Results
Respondent Profile
Of the 491 JSCCR institutions sent survey invitations, 150 (30.5%) began the survey, and 144 (29.3%) completed it. The interim report was presented at the 80 th JSCCR congress in Tokyo, Japan, on January 2014.
Reporting Content
More than 70% of laboratories reported the pathological diagnostic term (98.6%), depth of tumor invasion (96.0%), tumor size (87.2%), lymph-vascular invasion (96.0%),
Ki-67 index (80.5%), and mitotic count (70.5%). Conversely, the tumor stage was recorded in only 32.2% of the laboratories ( Figure 1 ).
Pathological Diagnostic Term and Staging
Half (50.0%) of the pathology laboratories reported the NET diagnostic term according 
Assessment of Ki-67 index and mitotic count
The Ki-67 index or mitotic counts are influenced by their assessment methods 15, 17 ; therefore, we evaluated their assessment method in routine practice. In 88.0% of respondent laboratories, the Ki-67 index was assessed using the hot spot method in On the other hands, NANETS suggested other staging system applicable to colorectal
NETs from the ENETS classification in 2011 4 . Recent analysis supports the use of the AJCC/UICC systems for G1 NETs, and the use of ENETS and NANETS systems for all NETs until there is further evidence for medication 10, [21] [22] [23] [24] [25] . The variation in different staging systems may result in less concordant reporting in the pathological staging in
Japan. This survey revealed that many pathology laboratories are using JCCC 7 th staging system which is not for NET staging, but for colorectal cancer. A unified staging system and education would be required for concordant pathological reporting
Most laboratories performed D2-40 and elastic stains to report high quality information on risk factors in addition to the conventional neuroendocrine markers.
Many items included in the previously reported minimum data set were also reported in these pathology laboratories 15 . Institutions belonging to the JSCCR, including many hospitals, perform intensive clinical investigations and treatments of colorectal cancer, and this can be reflected by the policies of the respondent institutions. However, some problems were also found.
14 Visual estimation of the Ki-67 index can be effective to distinguish very low rates (less than 1% in a G1 NET) from very high rates (>20% in a NEC), however, the subtle differences in proliferative rates between G1 and G2 NET are difficult to recognize accurately by this method . The WHO 2010 proposal for a more specific cell count number for the assessment of the Ki-67 index would be available to produce concordant data in the future 14, [29] [30] [31] . Next, we speculated that the time and effort necessary to assess the Ki-67 index and mitotic count may also be one cause of the discordant cell counts and fields. In a regional survey, it was reported that Japanese pathologists diagnose and report on 2500 cases per year on average (data not shown). We firstly elucidated that it takes 18.0 and 27.3 minutes only to assess the mitotic count in 50 fields with Ki-67 index in 500 and 2000 cells respectively. This seemed to limit the feasibility of this assessment method in pathology laboratories supporting a busy practice. Recently automatic assessment of the Ki-67 index was reported to be available in routine practice 26, 27 and such a method would assist in producing consistent data across laboratories. Standardization of these methods will be required for the introduction into routine practice. As for the mitotic count, automatic evaluation can be more difficult. However, in addition to the widespread standardization of the assessment method for the mitotic index, investigation of automatic analysis method will facilitate the production of concordant results in the future.
In conclusion, detailed pathology reporting was performed by the laboratories surveyed, but accurate recording of tumor stage was lacking in many Japanese pathology laboratories. There was also a reasonable acceptance of the WHO classification scheme for the use of diagnostic terms. However, a large variety of assessment methods for Ki-67 index and mitotic index were found. Recommended assessment method of Ki-67 index and mitotic count seemed to be low feasibility by its long required time.
Standardized and practical assessment method of Ki-67 index and mitotic count is still required to produce concordant reporting results of NETs across all laboratories. (b) The number of cells counted to assess the Ki-67 index was 500 or less (37.9%), 501 ～1000 (37.9%), 1001～1500 (15.5%), 1501～2000 (4.3%), and more than 2000 (4.3%).
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(c) The assessment methods of mitotic count were hot spot method (88.0%) and at random (9.4%).
(d) The number of high-power fields counted to evaluate mitotic count was 10 (71.0%), 20 (8.0%), and more than 50 (17.0%). 
